Arena Defends Obesity Drug After Phase III BLOOM Wilts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Arena is playing up the robust safety profile and approvability of its obesity drug lorcaserin after unveiling lackluster efficacy results from the Phase III BLOOM trial
You may also be interested in...
Orexigen Starts Partnership Talks On Obesity Drug Contrave
Firm stresses Phase III efficacy results will pass muster with FDA.
Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes
CEO hails positive Phase III data, but not all analysts are convinced.
Obesity Guidance Should Be More Lenient On Indications, Firms Tell FDA
A stipulation that patients should fail lifestyle modifications before they are eligible to enroll in clinical trials for obesity drugs needs to be modified, according to industry comments on an FDA draft guidance on development of weight management drugs